Dec 15, 2025
Sanofi (SNY) Stock: Falls After MS Drug Suffers Double Blow
Tolebrutinib failed phase 3 trial for primary progressive MS and faces FDA delay. Sanofi drops regulatory plans but continues work on other MS forms.
The post Sanofi (SNY) Stock: Falls After MS Drug Suffers Double Blow appeared first on Blockonomi.
Source: Blockonomi →Related News
- 6 days ago
Bitcoin (BTC) Price: Bitfinex Long Positions Surge to 28-Month Peak — Historical...
- 1 week ago
How a $100 Oil Shock Is Putting Bitcoin’s Digital Gold Status to the Test
- 1 week ago
Dogecoin’s Repeating Cycle Structure Points to Potential Markup Phase Ahead
- 1 week ago
S&P 500 Drops for Fifth Week as Crash Warnings Rise Amid Iran War Fears
- 1 week ago
StarkWare Co-Founder Defends ZK Technology Amid Canton, Ethereum, and Solana Riv...